

SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

Form 10-K

Annual Report Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934

For the fiscal year ended December 31, 1996 Commission File No. 0-11576

HARRIS & HARRIS GROUP, INC.

(Exact name of registrant specified in its charter)

New York

13-3119827

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

One Rockefeller Plaza, Rockefeller Center, New York, New York 10020

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (212) 332-3600

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock \$.01 par value

(Title of class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

--- ---

The aggregate market value of the Common Stock held by non-affiliates of Registrant as of March 14, 1997 was \$37,414,515 based on the last sale price as quoted by NASDAQ on such date (only officers and directors are considered affiliates for this calculation).

As of March 14, 1997, the registrant has 10,442,682 shares of common stock, par value \$.01 per share, outstanding.

TABLE OF CONTENTS

	Page
PART I	
Item 1. Business	1
Item 2. Properties	6
Item 3. Legal Proceedings	6
Item 4. Submission of Matters to a Vote of Security Holders	6
PART II	
Item 5. Market for Company's Common Equity and Related Stockholder Matters	7
Item 6. Selected Financial Data	8
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations	9

Item 8. Financial Statements and Supplementary Data	13
Item 9. Disagreements on Accounting and Financial Disclosure.	13

PART III

Item 10. Directors and Executive Officers of the Company	14
Item 11. Executive Compensation	18
Item 12. Security Ownership of Certain Beneficial Owners and Management. . .	20
Item 13. Certain Relationships and Related Transactions	21

PART IV

Item 14. Exhibits, Financial Statements, Schedules and Reports on Form 8-K	21
Signatures.	22
Exhibit Index	24

PART I

Item 1. Business

Harris & Harris Group, Inc. (the "Registrant" or "Company") is a venture capital investment company, operating as a Business Development Company ("BDC") under the Investment Company Act of 1940 (the "1940 Act"). The Company's objective is to achieve long-term capital appreciation, rather than current income, from its investments. The Company has invested a substantial portion of its assets in private development stage or start-up companies, and in the development of new technologies in a broad range of industry segments. These private businesses tend to be thinly capitalized, unproven, small companies that lack management depth and have not attained profitability or have no history of operations. The Company may also invest, to the extent permitted under the 1940 Act, in publicly traded securities, including high risk securities as well as investment grade securities. The Company may participate in expansion financing and leveraged buy out financing of more mature operating companies as well as other investments. As a venture capital company, the Company invests in and provides managerial assistance to its private investees which, in its opinion, have significant potential for growth. There is no assurance that the Company's investment objective will be achieved.

The Company was incorporated under the laws of the State of New York in August 1981. Prior to September 30, 1992, the Company was registered and filed under the reporting requirements of the Securities and Exchange Act of 1934 as an operating company. On that date the Company commenced operations as a closed-end, non-diversified investment company under the 1940 Act. On July 26, 1995, the Company elected to become a business development company subject to the provision of Sections 55 through 65 of the 1940 Act, as amended by the Small Business Incentive Act of 1980. As a BDC, the Company operates as an internally managed investment company whereby its officers and employees, under the general supervision of its Board of Directors, conduct its operations.

Venture Capital Investments

The Company has invested a substantial portion of its assets in private development stage or start-up companies. The Company may initially own 100 percent of the securities of a start-up investment for a period of time and may control such company for a substantial period. In connection with its venture capital investments, the Company may be involved in recruiting management, formulating operating strategies, product development, marketing and advertising, assisting in financial plans, as well as providing management in the initial start-up stages and establishing corporate goals. The Company may assist in raising additional capital for such companies from other potential investors and may subordinate its own investment to that of other investors. The Company may also find it necessary or appropriate to provide additional capital of its own. The Company may introduce such companies to potential joint venture partners, suppliers and customers. In addition, the Company may assist in establishing relationships with

investment bankers and other professionals. The Company may also assist with mergers and acquisitions. The Company may derive income from such companies for the performance of any of the above services. Because of the speculative nature of these investments and the lack of any market for such securities, there is significantly greater risk of loss than is the case with traditional investment securities. The Company expects that some of its venture capital investments will be a complete loss or will be unprofitable and that some will appear likely to become successful, but never realize their potential. The Company has been and will continue to be risk seeking rather than risk averse in its approach to its venture capital and other investments.

1

The Company may control a company for which it has provided venture capital, or it may be represented on the company's board of directors by one or more of its officers or directors, who may also serve as officers of such a company. Particularly during the early stages of an investment, the Company may in effect be conducting the operations of the company. As a venture company emerges from the developmental stage with greater management depth and experience, the Company expects that its role in the company's operations will diminish. The Company seeks to assist each company in establishing its own independent capitalization, management and board of directors. The Company expects to be able to reduce its active involvement in the management of its investment in those start-up companies that become successful by a liquidity event, such as a public offering or sale of a company.

The Company has invested a substantial portion of its assets in securities that do not pay interest or dividends and that are subject to legal or contractual restrictions on resale that may adversely affect the liquidity and marketability of such securities.

Intellectual Property

The Company believes there is a role for organizations that can assist in technology transfer. Scientists and institutions that develop and patent intellectual property increasingly seek the rewards of entrepreneurial commercialization of their inventions, particularly as governmental, philanthropic and industrial funding for research has become harder to obtain. The Company believes that several factors combine to give it a high value-added role to play in the commercialization of technology: its experience in organizing and developing successful new companies; its willingness to invest its own capital at the highest risk, seed stage; its access to high-grade institutional sources of intellectual property; its experience in mergers, acquisitions and divestitures; its access to and knowledge of the capital markets; and its willingness to do as much of the early work as it is qualified to do.

The Company's form of investment may include: 1) funding of research and development in the development of a technology; 2) obtaining licensing rights to intellectual property or patents; 3) outright acquisition of intellectual property or patents; and 4) formation and funding of companies or joint ventures to commercialize intellectual property. Income from the Company's investments in intellectual property or its development may take the form of participation in licensing or royalty income, fee income, or some other form of remuneration. At some point during the commercialization of a technology, the Company's investment may be transformed into ownership of securities of a development stage or start-up company as discussed above. Investing in intellectual property is highly risky.

2

Illiquidity of Investments

Many of the Company's investments consist of securities acquired directly from the issuer in private transactions. They may be subject to restrictions on resale or otherwise be illiquid. The Company does not anticipate that there will be any established trading market for such securities. Additionally, many of the securities that the Company may invest in will not be eligible for sale to the public without registration under the Securities Act of 1933, as amended, which could prevent or delay any sale by the Company of such investments or reduce the amount of proceeds that might otherwise be realized therefrom. Restricted securities generally sell at a

price lower than similar securities not subject to restrictions on resale. Further, even if a portfolio company or investee registers its securities and becomes a reporting company under the Securities and Exchange Act of 1934, the Company may be considered an insider by virtue of its board representation and would be restricted in sales of such company's securities.

Managerial Assistance

The Company believes that providing managerial assistance to its investees is critical to its business development activities. "Making available significant managerial assistance" as defined in the 1940 Act with respect to a business development company such as the Company means (a) any arrangement whereby a business development company, through its directors, officers, employees or general partners, offers to provide, and if accepted, does so provide, significant guidance and counsel concerning the management, operations, or business objectives and policies of a portfolio company; or (b) the exercise by a business development company of a controlling influence over the management or policies of a portfolio company by a business development company acting individually or as a part of a group acting together which controls such portfolio company. The Company is required by the 1940 Act to make significant managerial assistance available at least with respect to investee companies that the Company treats as qualifying assets for purposes of the 70 percent test (see "Regulation"). The nature, timing and amount of managerial assistance provided by the Company vary depending upon the particular requirements of each investee company.

The Company may be involved with its investees in recruiting management, product planning, marketing and advertising and the development of financial plans, operating strategies and corporate goals. In this connection, the Company may assist clients in developing and utilizing accounting procedures to efficiently and accurately record transactions in books of account, which will facilitate asset and cost control and the ready determination of results of operations. The Company also seeks capital for its investees from other potential investors and occasionally subordinates its own investment to those of other investors. The Company introduces its investees to potential suppliers, customers and joint venture partners and assists its investees in establishing relationships with commercial and investment bankers and other professionals, including management consultants, recruiters, legal counsel and independent accountants. The Company also assists with joint ventures, acquisitions and mergers.

3

In connection with its managerial assistance, the Company may be represented by one or more of its officers or directors on the board of directors of an investee. As an investment matures and the investee develops management depth and experience, the Company's role will become progressively less active. However, when the Company owns or on a pro forma basis could acquire a substantial proportion of a more mature investee company's equity, the Company remains active in and will frequently initiate planning of major transactions by the investee. The Company's goal is to assist each investee company in establishing its own independent and effective board of directors and management.

Need for Follow-On Investments

Following its initial investment in investees, the Company has made and anticipates that it will continue to make additional investments in such investees as "follow-on" investments, in order to increase its investment in an investee, and may exercise warrants, options or convertible securities that were acquired in the original financing. Such follow-on investments may be made for a variety of reasons including: 1) to increase the Company's exposure to an investee, 2) to acquire securities issued as a result of exercising convertible securities that were purchased in the original financing, 3) to preserve the Company's proportionate ownership in a subsequent financing, or 4) in an attempt to preserve or enhance the value of the Company's investment. There can be no assurance that the Company will make follow-on investments or have sufficient funds to make such investments; the Company will have the discretion to make any follow-on investments as it determines, subject to the availability of capital resources. The failure to make such follow-on investments may, in certain circumstances, jeopardize the continued viability of an investee and the Company's initial investment, or may result in a missed opportunity for the Company to increase its

participation in a successful operation.

Competition

Numerous companies and individuals are engaged in the venture capital business and such business is intensely competitive. Most of the competitors have significantly greater experience, resources and managerial capabilities than the Company and are therefore in a better position than the Company to obtain access to attractive venture capital investments.

Regulation

The Small Business Investment Incentive Act of 1980 modified the provisions of the 1940 Act that are applicable to a closed-end investment BDC. After filing its election to be treated as a BDC, a company may not withdraw its election without first obtaining the approval of holders of a majority of its outstanding voting securities. The following is a brief description of the 1940 Act, as modified by the Small Business Investment Incentive Act of 1980, and is qualified in its entirety by the reference to the full text of the 1940 Act and the rules thereunder by the Securities and Exchange Commission (the "SEC").

Generally, to be eligible to elect BDC status, a company must primarily engage in the business of furnishing capital and managerial expertise to companies which do not have ready access to capital through conventional financial channels. Such portfolio companies are termed "eligible portfolio companies." More specifically, in order to qualify as a BDC, a company must (i) be a domestic company; (ii) have registered a class of its securities or have filed a registration statement with the SEC pursuant to Section 12 of the Exchange Act of 1934; (iii) operate for the purpose of investing in the securities of certain types of portfolio companies, namely, immature or emerging companies and businesses suffering or just recovering from financial distress (see following paragraph); (iv) extend significant managerial assistance to such portfolio companies; (v) have a majority of "disinterested" directors (as defined in the 1940 Act) and (vi) file (or, under certain circumstances, intend to file) a proper notice of election with the SEC.

4

An eligible portfolio company generally is a domestic company that is not an investment company and that (i) does not have a class of securities registered on an exchange or included in the Federal Reserve Board's over-the-counter margin list; (ii) is actively controlled by a BDC and has an affiliate of a BDC on its board of directors or (iii) meets such other criteria as may be established by the SEC. Control under the 1940 Act is presumed to exist where a BDC owns 25 percent of the outstanding securities of the investee.

The 1940 Act prohibits or restricts companies subject to the 1940 Act from investing in certain types of companies, such as brokerage firms, insurance companies, investment banking firms and investment companies. Moreover, the 1940 Act limits the type of certain assets necessary for its operations (such as office furniture, equipment and facilities) if, at the time of acquisition, less than 70 percent of the value of the Company's assets consist of qualifying assets. Qualifying assets include: (i) securities of companies that were eligible portfolio companies at the time such company acquired their securities; (ii) securities of bankrupt or insolvent companies that were eligible at the time of such company's initial investment in those companies; (iii) securities received in exchange for or distributed in or with respect to any of the foregoing and (iv) cash items, government securities and high quality short-term debt. The 1940 Act also places restrictions on the nature of the transactions in which, and the persons for whom, securities can be purchased in order for the securities to be considered qualifying assets. Such restrictions include limiting purchases to transactions not involving a public offering and acquiring securities from either the portfolio company or their officers, directors or affiliates.

The Company is permitted by the 1940 Act, under specified conditions, to issue multiple classes of senior debt and a single class of preferred stock if its asset coverage, as defined in the 1940 Act, is at least 200 percent after the issuance of the debt or the preferred stock (i.e., such senior securities may not be in excess of 50 percent of its net assets). If

the value of the Company's assets, as defined, were to increase through the issuance of additional capital stock or otherwise, the Company would be permitted under the 1940 Act to issue senior securities.

The Company may sell its securities at a price that is below the prevailing net asset value per share only after a majority of its disinterested directors has determined that such sale would be in the best interest of the Company and its stockholders and upon the approval by the holders of a majority of its outstanding voting securities, including a majority of the voting securities held by non-affiliated persons. If the offering of the securities is underwritten, a majority of the disinterested directors must determine in good faith that the price of the securities being sold is not less than a price which closely approximates market value of the securities, less any distribution discount or commission. As defined by the 1940 Act, the term "majority of the Company's outstanding voting securities" means the vote of (i) 67 percent or more of the Company's Common Stock present at the meeting, if the holders of more than 50 percent of the outstanding Common Stock are present or represented by proxy or (ii) more than 50 percent of the Company's outstanding Common Stock, whichever is less.

5

Most of the transactions involving the Company and its affiliates (as well as affiliates of those affiliates) which were prohibited without the prior approval of the Commission under the 1940 Act prior to its amendment by the Small Business Investment Incentive Act are now permissible upon the prior approval of a majority of the Company's independent directors and a majority of the directors having no financial interest in the transactions. However, certain transactions involving certain closely affiliated persons of the Company, including its directors, officers, and employees, may still require the prior approval of the Commission. In general, (i) any person who owns, controls or holds power to vote, more than 5 percent of the Company's outstanding Common Stock; (ii) any director, executive officer or general partner of that person and (iii) any person who directly or indirectly controls, is controlled by, or is under common control with, that person, must obtain the prior approval of a majority of the Company's independent directors and, in some situations, the prior approval of the Commission, before engaging in certain transactions involving the Company or any company controlled by the Company. The 1940 Act generally does not restrict transactions between the Company and its portfolio companies. While a BDC may change the nature of its business so as to cease being a BDC (and in connection therewith withdraw its election to be treated as a BDC) only if authorized to do so by a majority vote (as defined in the 1940 Act) of its outstanding voting securities, stockholder approval of changes in other fundamental investment policies of a BDC is not required (in contrast to the general 1940 Act requirement, which requires stockholder approval for a change in any fundamental investment policy). The Company is entitled to change its diversification status without stockholder approval.

Item 2. Properties

The Company maintains its offices at One Rockefeller Plaza, Suite 1430, New York, New York 10020, where it leases approximately 4,700 square feet of office space pursuant to a lease agreement expiring in 2003.

Item 3. Legal Proceedings

None.

Item 4. Submission of Matters to a Vote of Security Holders

The Company did not submit any matters to a vote of its shareholders during the fourth quarter of the 1996 fiscal year.

6

PART II

Item 5. Market for Company's Common Equity and Related Stockholder Matters

Stock Transfer Agent

The Bank of New York, 101 Barclay Street, Suite 22W, New York, New

York 10286 (Telephone (800) 524-4458, Attention: Ms. Diane Ajjan) serves as transfer agent for the Company's common stock. Certificates to be transferred should be mailed directly to the transfer agent, preferably by registered mail.

Market Prices

The Company's common stock is traded on the NASDAQ National Market System under the NASDAQ symbol "HHGP." The following table sets forth the range of the high and low selling price of the Company's shares during each quarter of the last two years, as reported by the National Association of Securities Dealers, Inc.

<TABLE> <S>	<C>	<C>
1996 Quarter Ending	Low	High
March 31	\$5.625	\$7.875
June 30	\$5.500	\$7.375
September 30	\$4.000	\$5.875
December 31	\$3.625	\$4.875
1995 Quarter Ending	Low	High
March 31	\$4.875	\$6.375
June 30	\$4.375	\$5.125
September 30	\$4.625	\$5.875
December 31	\$4.375	\$8.125

</TABLE>

On February 19, 1991, the Company's Board of Directors suspended indefinitely the payment of dividends.

Shareholders

As of February 27, 1997, there were approximately 180 holders of record of the Company's common stock which, the Company has been informed, hold the Company's common stock for approximately 2,000 beneficial owners.

7

Item 6. Selected Financial Data

The following tables should be read in conjunction with the Financial Statements included in Item 8 of this Form 10-K.

<TABLE>
<CAPTION>

BALANCE SHEET DATA Financial Position as of December 31:

<S>	<C>	<C>	<C>	<C>	<C>
	1996	1995	1994	1993	1992
Total assets	\$ 38,555,290	\$ 37,524,555	\$ 32,044,073	\$ 34,534,724	\$ 29,377,482
Liabilities	\$ 2,622,687	\$ 962,646	\$ 733,271	\$ 1,785,427	\$ 6,724,139
Net asset value	\$ 35,932,603	\$ 36,561,909	\$ 31,310,802	\$ 32,749,297	\$ 22,653,343
Net asset value per share	\$ 3.44	\$ 3.54	\$ 3.43	\$ 3.66	\$ 2.71

Shares

outstanding 10,442,682 10,333,902 9,136,747 8,944,828 8,350,999

Operating Data for year ended December 31 unless otherwise noted:

	3 months ended December 31,				
	1996	1995	1994	1993	1992

Investment					
income	\$ 1,013,417	\$ 1,109,517	\$ 820,276	\$ 453,950	\$ 167,668
Net operating					
loss	(1,291,065)	(1,099,409)	(2,278,882)	(1,614,625)	(203,295)
Net realized					
(loss) gain on					
investments	(2,465,175)	1,371,349	96,856	23,590,570	(128,332)
Net realized					
(loss) income	(3,756,240)	271,940	(2,182,026)	21,975,945	(331,627)
Net increase (decrease)					
in unrealized					
appreciation on					
investments	2,967,248	158,219	(886,040)	(13,083,344)	(1,247,191)
Net (decrease) increase					
in net assets					
resulting from					
operations	(788,992)	430,159	(3,068,066)	8,892,601	(1,578,818)
(Decrease) increase					
in net assets					
resulting from					
operations					
per outstanding					
share	\$ (0.08)	\$ 0.04	\$ (0.34)	\$ 1.03	\$ (0.19)

</TABLE>

8

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Statement of Operations

The Company accounts for its operations under Generally Accepted Accounting Principles for investment companies. On this basis, the principal measure of its financial performance is captioned "Net increase (decrease) in net assets from operations," which is the sum of three elements. The first element is "Net operating loss," which is the difference between the Company's income from interest, dividends, and fees and its operating expenses, net of applicable income tax provisions (benefits). The second element is "Net realized gain (loss) on investments," which is the difference between the proceeds received from dispositions of portfolio securities and their stated cost, net of applicable income tax provisions (benefits). These two elements are combined in the Company's financial statements and reported as "Net realized income (loss)." The third element, "Net increase (decrease) in unrealized appreciation on investments," is the net change in the fair value of the Company's investment portfolio, net of increase (decrease) in deferred income taxes that would become payable if the unrealized appreciation were realized through the sale or other disposition of the investment portfolio.

"Net realized gain (loss) on investments" and "Net increase (decrease) in unrealized appreciation on investments" are directly related. When a security is sold to realize a gain (loss), net unrealized appreciation decreases (increases) and net realized gain increases (decreases).

Financial Condition

The Company's total assets and net assets were, respectively, \$38,555,290 and \$35,932,603 at December 31, 1996, versus \$37,524,555 and \$36,561,909 at December 31, 1995. Net asset value per share was \$3.44 at December 31, 1996, versus \$3.54 at December 31, 1995.

The Company's financial condition is dependent on the success of its investments. The Company has invested and expects to continue to invest a substantial portion of its assets in private development stage or start-up companies. These private businesses tend to be thinly capitalized, unproven, small companies that lack management depth or have no history of operations.

At December 31, 1996, 49 percent of the Company's \$39.0 million in total assets consisted of investments at fair value in private businesses, of which net unrealized appreciation was approximately \$5.0 million before taxes. At December 31, 1995, 35.5 percent of the Company's \$37.5 million in total assets consisted of investments at fair value in private businesses, of which net unrealized appreciation was approximately \$0.8 million.

9

A summary of the Company's investment portfolio is as follows:

<TABLE>

<S>	<C>	<C>
	December 31, 1996	December 31, 1995
Investments, at cost	\$ 28,981,093	\$ 33,826,696
Unrealized appreciation	6,667,589	2,102,593
	-----	-----
Investments, at fair value	\$ 35,648,682	\$ 35,929,289
	=====	=====

<FN>

The accumulated unrealized appreciation on investments net of deferred taxes is \$4,371,591 at December 31, 1996, versus \$1,404,343 at December 31, 1995.

</FN>

</TABLE>

Following an initial investment in a private company, the Company may make additional investments in such investee in order to: (1) increase its ownership percentage; (2) to exercise warrants or options that were acquired in a prior financing; (3) to preserve the Company's proportionate ownership in a subsequent financing or (4) attempt to preserve or enhance the value of the Company's investment. Such additional investments are referred to as "follow-on" investments. There can be no assurance that the Company will make follow-on investments or have sufficient funds to make additional investments. The failure to make such follow-on investments could jeopardize the viability of the investee company and the Company's investment or could result in a missed opportunity for the Company to participate to a greater extent in an investee's successful operations. The Company attempts to maintain adequate liquid capital to make follow-on investments in its private investee portfolio companies. The Company may elect not to make a follow-on investment either because it does not want to increase its concentration of risk or because it prefers other opportunities, even though the follow-on investment opportunity appears attractive.

The following table is a summary of the cash investments made by the Company in its private placement portfolio during the year ended December 31, 1996:

<TABLE>

<S>	<C>
	Amount
New Investments:	-----
BioSupplyNet, Inc.	\$ 575,000
Genomica Corporation	1,000,304
MultiTarget, Inc.	60,811
NeuroMetrix, Inc.	210,000
PowerVoice Technologies, Inc.	500,000
PureSpeech, Inc.	999,999

Sub-total	\$ 3,346,114
Follow-on Investments:	

nFX Corporation	\$ 440,000
Micracor, Inc.	103,000
Gel Sciences, Inc.	545,000

Sub-total	\$ 1,088,000
Exercise of Warrants Held:	

Princeton Video Image, Inc.	\$ 547,500

Total	----- \$ 4,981,614 =====
-------	--------------------------------

</TABLE>

Subsequent to December 31, 1996, the Company made follow-on investments of \$850,000 in PowerVoice Technologies, Inc. and \$500,000 in Highline Offshore Advisors, LLC. In addition, the Company signed loan agreements with two of its investee companies for up to \$750,000.

10

Results of Operations

Investment Income and Expenses:

The Company's principal objective is to achieve capital appreciation. Therefore, a significant portion of the investment portfolio is structured to maximize the potential for capital appreciation and provides little or no current yield in the form of dividends or interest. The Company does earn interest income from fixed-income securities, including U.S. Government Obligations. The amount of interest income earned varies based upon the average balance of the Company's fixed-income portfolio and the average yield on this portfolio.

The Company had interest income of \$803,819 in 1996, \$999,869 in 1995 and \$719,293 in 1994. The decrease is a result of a decline in the balance of the Company's fixed-income portfolio to pay operating expenses and to purchase non-income producing private portfolio investments. The Company also received consulting and administrative fees from certain portfolio companies which totaled \$68,185 in 1996 and \$88,209 in 1995.

Operating expenses were \$2,985,316 in 1996, \$2,806,141 in 1995 and \$4,364,806 in 1994. The increase from 1995 to 1996 is primarily owing to additional consulting fees incurred in 1996 related to prospective private portfolio investments. Operating expenses in 1994 included sign-up bonuses totaling \$1,000,000 to two executives hired by the Company. Most of the Company's operating expenses are related to employee and director compensation, office and rent expenses and consulting and professional fees (primarily legal and accounting fees).

Net operating losses before taxes were \$1,971,899 in 1996, \$1,696,624 in 1995 and \$3,544,530 in 1994.

The Company has in the past relied, and continues to rely to a large extent, upon proceeds from sales of investments, rather than investment income, to defray a significant portion of its operating expenses. Because such sales cannot be predicted with certainty, the Company attempts to maintain adequate working capital to provide for fiscal periods when there are no such sales.

11

Realized Gains and Losses on Sales of Portfolio Securities:

During the three years ended December 31, 1996, 1995 and 1994, the Company sold various investments, realizing a net loss of \$3,792,576, a net gain of \$2,109,768 and a net loss of \$71,396, respectively.

During 1996, the Company realized a loss on the sale of its equity interest in Sonex International Corporation. However, because the investment had been written off in 1994, the loss did not affect earnings in 1996. Also during 1996, the Company sold and realized a loss on the sale of its equity interest in Micracor Corporation.

During 1995, the Company sold various publicly traded securities, realizing a net pre-tax capital gain of \$2,109,768.

During 1994, the Company realized a net capital loss of \$71,396 from the disposition of various portfolio investments.

Unrealized Appreciation and Depreciation of Portfolio Securities:

Net unrealized appreciation on investments before taxes increased \$4,564,996 during the year ended December 31, 1996, from \$2,102,593 to \$6,667,589, owing primarily to increased valuations for Gel Sciences, Inc., Nanophase Technologies Corporation, PHZ Capital Partners, Princeton Video Image, Inc. and Biofield Corp; offset primarily by a decreased valuation of nFX Corporation.

Net unrealized appreciation on investments before taxes increased \$243,414 during the year ended December 31, 1995, from \$1,859,179 to \$2,102,593, owing primarily to increased valuations for CORDEX Petroleum, Inc., Questech Corporation, Alliance Pharmaceutical Corporation and Magellan Health Services, Inc.; offset primarily by a decreased valuation of Sonex International Corporation.

Net unrealized appreciation on investments before taxes decreased \$1,142,734 during the year ended December 31, 1994, from \$3,001,913 to \$1,859,179, owing primarily to unrealized losses in Sonex International Corporation and Dynecology Incorporated; offset by an increase in unrealized gain in Magellan Health Services, Inc.

Liquidity and Capital Resources

The Company reported total cash, receivables and marketable securities (the primary measure of liquidity) at December 31, 1996 of \$19,296,591, versus \$23,833,891 at December 31, 1995 and \$20,465,118 at December 31, 1994. Management believes that its cash, receivables and marketable securities provide the Company with sufficient liquidity for its operations.

12

Risks

Pursuant to Section 64(b)(1) of the Investment Company Act of 1940, a Business Development Company is required to describe the risk factors involved in an investment in the securities of such company inherent in the nature of the company's investment portfolio. There are significant risks inherent in the Company's venture capital business. The Company has invested a substantial portion of its assets in private development stage or start-up companies. These private businesses tend to be thinly capitalized, unproven, small companies that lack management depth and have not attained profitability or have no history of operations. Because of the speculative nature and the lack of a public market for these investments, there is significantly greater risk of loss than is the case with traditional investment securities. The Company expects that some of its venture capital investments will be a complete loss or will be unprofitable and that some will appear to be likely to become successful but never realize their potential. The Company has been risk seeking rather than risk averse in its approach to venture capital and other investments. Neither the Company's investments nor an investment in the Company is intended to constitute a balanced investment program. The Company does not currently pay or intend to pay cash dividends. The Company has in the past relied and continues to rely to a large extent upon proceeds from sales of investments rather than investment income to defray a significant portion of its operating expenses.

Item 8. Financial Statements and Supplementary Data

See Index to Financial Statements for a list of the Financial Statements and Supplementary Data included in this Form 10-K.

Item 9. Disagreements on Accounting and Financial Disclosure

None.

13

PART III

Item 10. Directors and Executive Officers of the Company

OFFICERS

- - - - -

* Charles E. Harris, Chairman and Chief Executive Officer. For additional information about Mr. Harris, please see the Directors' biographical

information section below.

Mel P. Melsheimer, age 57, has served as President, Chief Operating Officer and Chief Financial Officer since February 1997. Harris & Harris Group has employed Mel P. Melsheimer as a nearly full-time consultant since 1994. Mr. Melsheimer has had extensive entrepreneurial experience as well as senior operational and financial management responsibilities with public and privately owned companies. Mr. Melsheimer has served as a consultant to the Company or as an officer of an investee company since March 1994. From November 1992 to February 1994, he served as Executive Vice President, Chief Operating Officer and Secretary of Dairy Holdings, Inc. From June 1991 to August 1992, he served as President and Chief Executive Officer of Land-O-Sun Dairies as well as Executive Vice President of Finevest Foods, Inc. From March 1989 to May 1991, he served as Vice President, Chief Financial Officer and Treasurer of Finevest Foods, Inc. From January 1984 to February 1989, he served as Chairman, Chief Executive Officer and Founder of PHX Pacific, Inc. and President and Chief Executive Officer of MPM Capital Corp. From January 1981 to December 1983, he served as Executive Vice President and Chief Operating Officer of AZL Resources. From November 1975 to December 1980, he served as Executive Vice President and Chief Financial Officer of AZL Resources. From January 1968 to November 1975, he served in a financial capacity before becoming Vice President and Chief Financial Officer of Pepsi-Cola Company, PepsiCo, Inc. in 1972. He was graduated from the University of Southern California (MBA) and Occidental College (B.A., Economics).

David C. Johnson, Jr., age 40, joined the Company in February 1994, as a Senior Vice President and has served as Executive Vice President since January 1995. From 1984, until joining the Company, Mr. Johnson served as a Vice President of Salomon Brothers Inc. He was graduated from The Darden School at the University of Virginia (MBA, 1984) and the University of North Carolina at Chapel Hill (B.A., 1978).

Rachel M. Pernia, age 37, has served since January 1992 as a Vice President and Controller of the Company and as Treasurer since November 1994. From 1988 until Ms. Pernia joined the Company, she was employed as Assistant Controller for Cellcom Corp. From 1985 through 1988, she was employed as a senior corporate accountant by Bristol-Myers Squibb Company. She was graduated from Rutgers University (B.A., 1981) and is a certified public accountant.

14

DIRECTORS

Dr. C. Wayne Bardin, age 61, was elected to the Company's Board of Directors in December 1994. Dr. Bardin's professional appointments have included: Vice President, The Population Council; Professor of Medicine, Chief of the Division of Endocrinology, The Milton S. Hershey Medical Center of Pennsylvania State University; and Senior Investigator, Endocrinology Branch, National Cancer Institute. Dr. Bardin also serves as a consultant to several pharmaceutical companies. He has directed basic and clinical research leading to over 500 publications and patents. He has negotiated 15 licensing and manufacturing agreements. He has directed clinical R&D under 18 INDs filed with the U.S. FDA. Dr. Bardin has been appointed to the editorial boards of 15 journals. He has also served on national and international committees and boards for NIH, WHO, The Ford Foundation, and numerous scientific societies. Dr. Bardin received a B.A. from Rice University; a M.S. and M.D. from Baylor University and a Doctor Honoris Causa from the University of Caen, and the University of Paris.

G. Morgan Browne, age 62, was elected to the Company's Board of Directors in June 1992. Since 1985, Mr. Browne has been Administrative Director of the Cold Spring Harbor Laboratory, a private not-for-profit institution that conducts research and education programs in the fields of molecular biology and genetics. In prior years, he was active in the management of numerous scientifically based companies as an individual consultant or as an associate of Laurent Oppenheim Associates, Industrial Management Consultants. He is a director of Oncogene Science, Inc. (principally engaged in drug discovery based on gene transcription), a founding director of the New York Biotechnology Association, and a founding director and Treasurer of the Long Island Research Institute. He is a graduate of Yale University and attended New York University Graduate School

of Business.

Harry E. Ekblom, age 68, has been a director of the Company since 1984. Mr. Ekblom currently serves as Vice Chairman of A.T. Hudson & Co., Inc. and President of Harry E. Ekblom & Co., Inc., each of which is engaged in the business of management consulting. He became President of Harry E. Ekblom & Co., Inc. in 1984 and joined A.T. Hudson in March 1985. Before 1984, he was employed by European American Bank as the Chairman of its Board of Directors and Chief Executive Officer. Mr. Ekblom is a director of Pan Energy Corp. (principally engaged in interstate transmission of natural gas) and The Commercial Bank of New York. He is a graduate of Columbia College and the New York University School of Law, a member of the New York Bar, and holds honorary degrees from Hofstra University and Pace University.

Dugald A. Fletcher, age 67, was elected to the Company's Board of Directors in June 1996. Mr. Fletcher has been President of Fletcher & Company, Inc., a management consulting firm, for the past five years. He is also Chairman of Binnings Building Products Company, Inc. and an Advisor to the Gabelli Growth Fund and a Director of Gabelli Convertible Securities Fund. Previously, he was an advisor to the Gabelli/Rosenthal LP, a leveraged buyout fund; Chairman of Keller Industries (building and consumer products); Director and investor in Mid-Atlantic Coca-Cola Bottling Company; Senior Vice President of Booz-Allen & Hamilton and President of Booz-Allen Acquisition Services; Executive Vice President and a Director of Paine Webber, Inc.; and President of Baker, Weeks and Co., Inc. He is a graduate of Harvard College and of Harvard Business School.

15

* Charles E. Harris, age 54, has been a director of the Company and Chairman of its Board of Directors since April 1984. He has served as Chief Executive Officer of the Company since July 1984. From April 1990 to August 1991, he served as Chairman of publicly owned Ag Services of America, Inc., in which the Company then held an equity interest. From its formation in November 1989 until June 1990, he served as Chairman and Chief Executive Officer of publicly owned Molten Metal Technology, Inc., which the Company cofounded and in which the Company then held an equity interest. From July 1986 to January 1989, he served as Chairman of publicly owned Re Capital Corporation, which the Company founded and in which the Company then held an equity interest. From July 1984 to July 1985, he served as a director and was the control person of publicly owned Alliance Pharmaceutical, which the Company founded and in which the Company then held an equity interest. Prior to 1984, he was Chairman of Wood, Struthers and Winthrop Management Corp., the investment advisory subsidiary of Donaldson, Lufkin & Jenrette. He was a member of the Advisory Panel for the Congressional Office of Technology Assessment. He is a Trustee of The Institute for Genomic Research, and a director of the insurance company Dearborn Risk Management, Inc. He is a member of the New York Society of Security Analysts. Among his eleemosynary activities, he is a life-sustaining fellow at the Massachusetts Institute of Technology and a member of the President's Council at Cold Spring Harbor Laboratory. He was graduated from Princeton University (A.B., 1964) and the Columbia University Graduate School of Business (MBA, 1967).

Charles F. Hays, age 51, joined the Board as a director in March 1995. Since 1993, Mr. Hays has been Senior Vice President, Chief Financial and Administrative Officer of Mid Ocean Ltd. His positions have included: Managing Director & Chief Financial and Administrative Officer of Marsh & McLennan, Incorporated, from 1984 to 1993; Vice President and Treasurer of the Guy Carpenter & Company subsidiary of Marsh & McLennan Companies, from 1979 to 1984; Assistant Vice President of Corporate Development of Marsh & McLennan Companies, from 1977 to 1979; Assistant Treasurer of Morgan Guaranty Trust Company, from 1975 to 1977; and Deputy Director of AmerAsian Group of Companies, from 1971 to 1972. He is a graduate of the University of Kansas and Stanford University Graduate School of Business.

Jon J. Masters, age 59, was elected to the Company's Board of Directors in February 1992. Since July 1996, Mr. Masters has been Vice Chairman of Robb Peck McCooey Specialist Corporation. Prior to that, since 1976, he was a member of the law firm of Christy & Viener, which he cofounded. Mr. Masters is a graduate of Princeton University and Harvard Law School.

Glenn E. Mayer, age 71, has been a director of the Company since 1981. In December 1991, Mr. Mayer joined, as a Senior Vice President, the

Investment Banking division of Reich & Company. Reich & Co. is now a division of Fahnstock & Company, Inc., a member firm of the New York Stock Exchange. For fifteen years prior to that, he was employed by Jesup & Lamont Securities Co. and its successor firms, in the Corporate Finance department. Mr. Mayer is a graduate of Indiana University.

William R. Polk, age 68, has been a director of the Company since August 1988. For the last seven years, Mr. Polk has been an author and self-employed consultant. He is the former President of the Adlai Stevenson Institute of International Affairs, a former member of the Policy Planning Council of the United States Department of State, and a former Professor of the University of Chicago and Harvard University. Mr. Polk is a graduate of Harvard University and Oxford University.

16

James E. Roberts, age 51, was elected to the Company's Board of Directors in June 1995. Since May 1995, Mr. Roberts has been Vice Chairman of Trenwick America Reinsurance Corporation. During the nine years prior to that, Mr. Roberts held the following positions at Re Capital Corporation: President and Chief Executive Officer, from 1992 to 1995; President and Chief Operating Officer, 1991 to 1992; Director since 1989 and Senior Vice President, 1986 to 1991; President and Chief Executive Officer of the Company's principal operating subsidiary, Re Capital Reinsurance Corporation from 1991 to 1995. Mr. Roberts has also served as Senior Vice President and Chief Underwriting Officer of North Star Reinsurance Corporation, from 1979 to 1986; Vice President of Rollins Burdick Hunter of New York, Inc., 1977 to 1979; Secretary of American Home Assurance/National Union Insurance Group of American International Group, Inc., 1973 to 1977; and commercial casualty underwriter at Continental Insurance Company, 1972 to 1973. Mr. Roberts is a graduate of Cornell University.

Robert B. Schulz, age 39, was elected to the Company's Board of Directors in February 1997. In February 1997, Mr. Schulz joined C B Health Ventures, L.P. as a Venture Partner. Prior to that, he served as the Company's President and Chief Operating Officer from March 1994 to his resignation in February 1997. From 1984, until joining the Company, he was employed by CS First Boston Corporation, most recently as a Director in the Insurance Group. Mr. Schulz received his MBA degree from Columbia University Graduate School of Business in 1983. Prior to attending Columbia University, he was employed as a research engineer in the Alternate Energy Group of Chevron Research Company and as a project manager of Dynecology, Incorporated, a high technology, family owned engineering research firm. He graduated from the Massachusetts Institute of Technology in 1979 with his B.S. and M.S. degrees in chemical engineering.

* Charles E. Harris is an "interested person" of the Company, as defined in the Investment Company Act of 1940, as an owner of more than five percent of the Company's stock, as a control person and as an officer of the Company.

17

Item 11. Executive Compensation

Summary Compensation Table

The following table sets forth a summary for each of the last three years of the cash and non-cash compensation awarded to, earned by, or paid to the Chief Executive Officer of the Company and the other executive officers of the Company, whose individual remuneration exceeded \$100,000 for the year ended December 31, 1996.

<TABLE>

Name and Principal Position	Annual Compensation		Long Term Compensation Awards		All Other Compensation
	Year	Salary	Bonus	Compensation	
	(\$)	(\$)	(\$)(1)	(#)	(\$)(2)

Charles E. Harris	1996	595,246	--	--	--	9,500
Chairman & CEO	1995	592,400	--	--	160,000	9,240
(3)	1994	605,739	--	--	--	9,240
Robert B. Schulz	1996	207,194	--	--	--	9,500
President & COO	1995	201,014	--	--	250,000	9,240
(5)	1994	146,908	500,000	--	--	--
C. Richard Childress	1996	262,200	--	--	--	--
CFO & EVP	1995	254,953	--	--	75,000	9,240
(4)	1994	264,458	--	--	--	9,240
David C. Johnson, Jr.	1996	197,763	--	--	--	9,500
EVP (5)	1995	192,500	--	--	200,000	9,240
	1994	158,246	500,000	--	--	9,240

<FN>

- (1) Amounts of "Other Annual Compensation" earned by the named executive officers for the periods presented did not meet the threshold reporting requirements.
- (2) Amounts reported represent the Company's contributions on behalf of the named executive to the Harris & Harris Group, Inc. 401(k) Plan described below.
- (3) As of August 15, 1990, Mr. Harris entered into a non-competition and employment contract with the Company that was amended on June 30, 1992, January 3, 1993, and June 30, 1994 (the "Employment Contract"). The term of the Employment Contract expires on December 31, 1999.

Mr. Harris is to receive compensation under his Employment Contract in the form of salary and other benefits. Annual base salary are to be increased annually as of January 1 of each year to reflect inflation and in addition may be increased by such amounts as the Board deems appropriate.

The Employment Contract provides Mr. Harris with life insurance for the benefit of his designated beneficiaries in the amount of \$2,000,000. The Employment Contract also provides reimbursement for uninsured medical expenses, not to exceed \$5,000 per annum, adjusted for inflation, over the period of the contract, and disability insurance in the amount of 100 percent of his base salary.

The Employment Contract provides severance pay in the event of termination without cause or by constructive discharge and also provides for certain death benefits payable to the surviving spouse, for a period of two years, equal to the executive's base salary.

18

In addition, Mr. Harris is entitled to receive severance pay pursuant to the severance compensation agreement that he entered into with the Company, effective August 15, 1990. The severance compensation agreement provides that if, following a change in control of the Company, as defined in the agreement, such individual's employment is terminated by the Company without cause or by the executive within one year of such change in control, the individual shall be entitled to receive compensation in a lump sum payment equal to 2.99 times the individual's average annualized compensation and payment of other welfare benefits. If the executive's termination is without cause or is a constructive discharge, the amount payable under the Employment Contract will be reduced by the amounts paid pursuant to the severance compensation agreement.

- (4) On October 1, 1996, Mr. Childress resigned as Executive Vice President and Chief Financial Officer of the Company. He currently is a consultant to the Company. The numbers exclude \$30,450, \$28,960 and \$28,260 for 1996, 1995 and 1994, respectively, of non-accountable office expense allowance received by Mr. Childress.
- (5) Bonus amounts represent sign-up remuneration received upon beginning employment with the Company during 1994.

</FN>

</TABLE>

There were no stock options granted to the executive officers included in the above table during the year ended December 31, 1996.

19

Item 12. Security Ownership of Certain Beneficial Owners and Management

Security ownership of Directors, Nominees and Officers and other principal holders of the Company's voting securities

The following table sets forth certain information with respect to beneficial ownership (as that term is defined in the rules and regulations of the Securities and Exchange Commission) of the Company's common stock as of March 14, 1997 by (1) each person who is known by the Company to be the beneficial owner of more than five percent of the outstanding common stock, (2) each director of the Company, (3) each current executive officer listed in the Summary Compensation Table and (4) all directors and executive officers of the Company as a group. Except as otherwise indicated, to the Company's knowledge, all shares are beneficially owned and investment and voting power is held as stated by the persons named as owners.

<TABLE>

<S> Name and Address of Beneficial Owner	<C> Number of Shares of Common Stock Owned	<C> Percent of Class (1)
Charles E. and Susan T. Harris One Rockefeller Plaza, Suite 1430 New York, NY 10020	1,690,988 (2)	15.60%
American Bankers Insurance Group 11222 Quail Roost Drive Miami, FL 33157	1,075,269 (3)	10.30%
Jordan Financial Services Group 1751 Mound Street, Suite 1A Sarasota, FL 34236	1,404,011 (4)	13.44%
C. Wayne Bardin	20,000 (6)	*
G. Morgan Browne	50,000 (5)	*
Harry E. Ekblom	55,000 (5)	*
Dugald A. Fletcher	20,000 (6)	*
Charles F. Hays	26,300 (6)	*
David C. Johnson, Jr.	337,574 (7)	3.18%
Jon J. Masters	50,000 (5)	*
Glenn E. Mayer	72,000 (5)(8)	*
Mel P. Melsheimer	305,072 (10)	2.84%
William R. Polk	71,000 (5)	*
James E. Roberts	22,000 (6)	*
Robert B. Schulz	131,845 (9)	1.25%
All Directors and Officers as a group (15 persons)	2,959,779	24.87%

* Less than one percent of issued and outstanding stock.

20

<FN>

- (1) Shares of common stock subject to options and warrants are deemed outstanding for computing the percentage of class of the person or group holding such options or warrants, but are not deemed outstanding for computing the percentage of class of any other person.
- (2) Includes 504,732 shares for which Mrs. Harris has sole investment power; 766,655 shares for which Mr. Harris has sole investment power; 21,996 shares owned by a child for which Mrs. Harris has sole voting and dispositive power; 1,271,387 shares for which Mr. Harris has sole voting power, and 237,605 shares subject to currently exercisable warrants for which Mr. Harris has sole investment power. Excludes 130,000 shares owned by the Susan T. and Charles E. Harris Foundation in which Charles E. Harris and Susan T. Harris are designated trustees; voting and dispositive power are vested with the trustees. On August 17, 1995, the Company granted Mr. Harris stock options to purchase 160,000 shares of common stock that vest over a five-year period, of which 32,000 have vested. The total shares have been included in the table.
- (3) Represents shares owned by subsidiaries of American Bankers Insurance Group, Inc.
- (4) Represents shares owned by Jordan Financial Services Group as of March 12, 1997. Jordan Financial Services Group is a registered investment advisor that holds these shares for investment purposes only on behalf of various clients.
- (5) Includes option to purchase 50,000 shares.
- (6) Includes option to purchase 20,000 shares, which vest over a five-year period. The total shares have been included in the table.
- (7) On August 17, 1995, the Company granted Mr. Johnson stock options to purchase 200,000 shares of common stock that vest over a five-year period, of which 40,000 have vested. The total shares have been included in the table.
- (8) Includes 2,000 shares owned by Mrs. Mayer.
- (9) On August 17, 1995, the Company granted Mr. Schulz stock options to purchase 250,000 shares of common stock that vest over a five-year period, of which 50,000 have vested. The vested shares have been included in the table. On February 14, 1997, Mr. Schulz resigned as President, COO & CCO from Harris & Harris Group, Inc. and was voted a Director and granted an option to purchase 20,000 shares of common stock that vest over a five-year period. Unless Mr. Schulz exercises the 50,000 stock options by May 14, 1997, the vested options will expire.
- (10) On February 10, 1997, the Company granted Mr. Mel P. Melsheimer stock options to purchase 300,000 shares of common stock that vest over a five-year period. The total shares have been included in this table.

</FN>

</TABLE>

Item 13. Certain Relationships and Related Transactions

There were no relationships or transactions within the meaning of this item during the year ended December 31, 1996.

PART IV

Item 14. Exhibits, Financial Statements, Schedules and Reports on Form 8-K

(a) Exhibits. The exhibits which are filed with this Form 10-K or incorporated herein by reference are set forth in the Exhibit Index on page 24.

(b) Reports on Form 8-K. The Company did not file any reports on Form 8-K during the last quarter of 1996.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HARRIS & HARRIS GROUP, INC.

Date: March 31, 1997

By: /s/

Charles E. Harris
Chairman of the Board

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

Signatures	Title	Date
-----	----	----
/s/ ----- Charles E. Harris	Chairman of the Board, Chief Compliance Officer and Chief Executive Officer	March 31, 1997
/s/ ----- Mel P. Melsheimer	President, Chief Operating Officer and Chief Financial Officer	March 31, 1997
/s/ ----- David C. Johnson, Jr.	Executive Vice President	March 31, 1997
/s/ ----- Rachel M. Pernia	Vice President, Controller, Treasurer and Principal Accounting Officer	March 31, 1997
	22	
/s/ ----- C. Wayne Bardin	Director	March 21, 1997
/s/ ----- G. Morgan Browne	Director	March 21, 1997
/s/ ----- Harry E. Ekblom	Director	March 21, 1997
/s/ ----- Dugald A. Fletcher	Director	March 21, 1997
/s/ ----- Charles F. Hays	Director	March 21, 1997
/s/ ----- Jon J. Masters	Director	March 31, 1997

/s/

Glenn E. Mayer Director March 21, 1997

/s/

William R. Polk Director March 21, 1997

/s/

James E. Roberts Director March 21, 1997

/s/

Robert B. Schulz Director March 21, 1997

23

EXHIBIT INDEX

The following exhibits are filed with this report or are incorporated herein by reference to a prior filing, in accordance with Rule 12b-32 under the Securities Exchange Act of 1934. (Asterisk denotes exhibits filed with this report.)

Exhibit No. Description

-
- 3.1(a) Restated Certificate of Incorporation of the Company, as amended, incorporated by reference to Exhibit 3.1 (a) to the Company's Form 10-K for the year ended December 31, 1995.
 - 3.1(b) Restated By-laws of the Company, incorporated by reference to Exhibit 3.1(b) to the Company's Form 10-K for the year ended December 31, 1995.
 - 4.1 Specimen certificate of common stock certificate, incorporated by reference to Exhibit 4 to Company's Registration Statement on Form N-2 filed October 29, 1992.
 - 8.1 Harris & Harris Group, Inc. 1988 Stock Option Plan, as amended and restated, incorporated by reference to Exhibit 8.1 to the Company's Form 10-K for the year ended December 31, 1995.
 - 9.1 Harris & Harris Group, Inc. Custodian Agreement with JP Morgan, incorporated by reference to Exhibit 9.1 to the Company's Form 10-K for the year ended December 31, 1995.
 - 10.1 Employment Agreement by and between the Company and Charles E. Harris dated August 15, 1990, incorporated by reference to Exhibit 10 (r) to the Company's Annual Report on Form 10-K for the year ended December 31, 1990.
 - 10.2 Amendment No.1 to the Employment Agreement dated as of August 15, 1990 between the Company and Charles E. Harris dated as of June 30, 1992, incorporated by reference to Exhibit 10.2 to the Company's Registration Statement in Form N-2 filed on October 29, 1992.
 - 10.3 Amendment No.2 to the Employment Agreement dated as of August 15, 1990 between the Company and Charles E. Harris dated as of January 6, 1993, incorporated by reference to Exhibit 10.22 to the Company's Registration Statement in Form N-2 filed on December 3, 1993.
 - 10.4 Amendment No.3 to the Employment Agreement dated as of August 15, 1990 between the Company and Charles E. Harris dated as of June 30, 1994.

24

- 10.5 Severance Compensation Agreement by and between the Company and Charles E. Harris dated August 15, 1990, incorporated by reference to exhibit 10 (s) to the Company's Annual Report on Form 10-K for the year ended December 31, 1990.
- 10.11 Warrant issued by the Company to Charles E. Harris dated September 23, 1985 as clarified and restated on May 1, 1989, incorporated by reference to Exhibit 10 (n) to the Company's Annual Report on Form 10-K for the year ended December 31, 1989.
- 10.13 Stock Purchase Agreement, Standstill Agreement and Termination and Release by and among Harris & Harris Group, Inc. and American Bankers Life Assurance Company of Florida dated May 18, 1995, incorporated by reference to Exhibit 10.13 to the Company's Form 10-K for the year ended December 31, 1995.
- 10.14 Form of Indemnification Agreement which has been established with all directors and executive officers of the Company, incorporated by reference to Exhibit 10.14 to the Company's Form 10-K for the year ended December 31, 1995.
- 24* Consent of Arthur Andersen LLP

25

HARRIS & HARRIS GROUP, INC.
INDEX TO FINANCIAL STATEMENTS AND SCHEDULES

The following reports and financial schedules of Harris & Harris Group, Inc. are filed herewith and included in response to Item 14(a).

Documents -----	Page ----
Report of Independent Public Accountant	27
 Financial Statements -----	
Statements of Assets and Liabilities as of December 31, 1996 and 1995	28
Statements of Operations for the years ended December 31, 1996, 1995 and 1994	29
Statements of Cash Flows for the years ended December 31, 1996, 1995 and 1994.	30
Statements of Changes in Net Assets for the years ended December 31, 1996, 1995 and 1994.	31
Schedule of Investments as of December 31, 1996 .	32-35
Footnote to Schedule of Investments	36-39
Notes to Financial Statements	40-46
Selected Per Share Data and Ratios for the years ended December 31, 1996, 1995, 1994 and 1993 and the three month period ended December 31, 1992	47

Schedules other than those listed above have been omitted because they are not applicable or the required information is presented in the financial statements and/or related notes.

26

REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS

To Harris & Harris Group, Inc.:

We have audited the accompanying statements of assets and liabilities

of Harris & Harris Group, Inc. (a New York corporation) as of December 31, 1996 and 1995, including the schedule of investments, as of December 31, 1996, and the related statements of operations, cash flows and changes in net assets for the three years ended December 31, 1996, and the selected per share data and ratios for each of the four years ended December 31, 1996 and the period from commencement of investment company operations (October 1, 1992) to December 31, 1992. These financial statements and selected per share data and ratios are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and selected per share data and ratios based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and selected per share data and ratios are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned as of December 31, 1996 and 1995, by correspondence with the custodian and brokers. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

As explained in Note 2, the financial statements include securities valued at \$18,825,365 (52.4 percent of net assets), whose values have been estimated by the Board of Directors in the absence of readily ascertainable market values. However, because of the inherent uncertainty of valuation, those estimated values may differ significantly from the values that would have been used had a ready market for the securities existed, and the differences could be material.

In our opinion, the financial statements and selected per share data and ratios referred to above present fairly, in all material respects, the financial position of Harris & Harris Group, Inc. as of December 31, 1996 and 1995, the results of its operations, its cash flows and the changes in its net assets for the three years ended December 31, 1996, and the selected per share data and ratios for each of the four years ended December 31, 1996 and the three month period ended December 31, 1992, in conformity with generally accepted accounting principles.

Arthur Andersen LLP

New York, New York
February 10, 1997

27

<TABLE>
<CAPTION>

STATEMENTS OF ASSETS AND LIABILITIES

ASSETS

<S>	<C>	<C>
	December 31, 1996	December 31, 1995
Investments, at value (See accompanying schedule of investments and notes) . . .	\$ 35,648,682	\$ 35,929,289
Cash and cash equivalents.	155,440	364,354
Receivable from brokers.	0	205,789
Interest receivable.	198,342	300,718
Taxes receivable (Note 6).	2,119,492	367,929
Prepaid expenses	81,501	86,976
Other assets	351,833	269,500
	-----	-----
Total assets	\$ 38,555,290	\$ 37,524,555
	=====	=====

LIABILITIES & NET ASSETS

Accounts payable and accrued liabilities	\$ 374,326	\$ 352,129
Deferred rent.	60,914	59,887

Deferred income tax liability (Note 6)	2,187,447	550,630
	-----	-----
Total liabilities	2,622,687	962,646
Commitments and contingencies (Note 7)		
	-----	-----
Net assets	\$ 35,932,603	\$ 36,561,909
	=====	=====

Net assets are comprised of:

Preferred stock, \$0.10 par value, 2,000,000 shares authorized; none issued	\$ 0	\$ 0
Common stock, \$0.01 par value, 25,000,000 shares authorized; 10,442,682 issued and outstanding at 12/31/96 and 10,333,902 issued and outstanding at 12/31/95 . . .	104,427	103,339
Additional paid in capital	15,850,576	15,691,978
Accumulated net realized income	15,606,009	19,362,249
Accumulated unrealized appreciation of investments, net of deferred tax liability of \$2,295,998 at 12/31/96 and \$698,250 at 12/31/95	4,371,591	1,404,343
	-----	-----
Net assets	\$ 35,932,603	\$ 36,561,909
	=====	=====

Shares outstanding	10,442,682	10,333,902
	-----	-----
Net asset value per outstanding share . .	\$ 3.44	\$ 3.54
	=====	=====

The accompanying notes are an integral part of these financial statements.

</TABLE>

<TABLE>
<CAPTION>

STATEMENTS OF OPERATIONS

<S>	<C>	<C>	<C>
	Year Ended	Year Ended	Year Ended
	December 31, 1996	December 31, 1995	December 31, 1994
Investment income:			
Interest from:			
Fixed-income securities	\$ 803,819	\$ 999,869	\$ 719,293
Affiliated companies . .	40,779	11,222	11,913
Dividend income--unaffiliated companies	8,024	8,436	88,067
Consulting and administrative fees . . .	68,185	88,209	0
Other income	92,610	1,781	1,003
	-----	-----	-----
Total investment income	1,013,417	1,109,517	820,276
Expenses:			
Salaries and benefits . .	1,524,826	1,560,132	2,061,981
Sign-up bonuses	0	0	1,000,000
	-----	-----	-----
Total salaries and benefits	1,524,826	1,560,132	3,061,981
Administration and operations	474,537	440,605	424,714
Professional fees	675,241	461,526	421,865
Depreciation and amortization	57,426	161,876	271,430
Rent	160,601	124,713	114,667
Directors' fees and expenses	80,702	40,836	52,816
Custodian fees	11,983	16,453	17,333
	-----	-----	-----
Total expenses	2,985,316	2,806,141	4,364,806
Operating loss before income taxes	(1,971,899)	(1,696,624)	(3,544,530)

Income tax benefit (Note 6)	680,834	597,215	1,265,648
Net operating loss	(1,291,065)	(1,099,409)	(2,278,882)
Net realized (loss) gain on investments:			
Realized (loss) gain on sale of investments . .	(3,792,576)	2,109,768	(71,396)
Total realized (loss) gain (3,792,576)		2,109,768	(71,396)
Income tax benefit (provision) (Note 6) . .	1,327,401	(738,419)	168,252
Net realized (loss) gain on investments	(2,465,175)	1,371,349	96,856
Net realized (loss) income	(3,756,240)	271,940	(2,182,026)
Net increase (decrease) in unrealized appreciation on investments:			
Increase as a result of investment sales . . .	2,525,548	337,577	7,955
Decrease as a result of investment sales . . .	0	(562,765)	(1,223,026)
Increase on investments held	4,112,413	1,002,347	1,028,961
Decrease on investments held	(2,072,965)	(533,745)	(956,624)
Change in unrealized appreciation (depreciation) on investments . . .	4,564,996	243,414	(1,142,734)
Income tax (provision) benefit (Note 6) . . .	(1,597,748)	(85,195)	256,694
Net increase (decrease) in unrealized appreciation on investments	2,967,248	158,219	(886,040)
Net (decrease) increase in net assets from operations:			
Total	\$ (788,992)	\$ 430,159	\$(3,068,066)
Per outstanding share . . .	\$ (0.08)	\$ 0.04	\$ (0.34)

</TABLE>
The accompanying notes are an integral part of these financial statements.

<TABLE>
<CAPTION>

STATEMENTS OF CASH FLOWS

<S> <C> <C> <C>

Year Ended Year Ended Year Ended
December 31, 1996 December 31, 1995 December 31, 1994

Cash flows (used in) provided by operating activities:			
Net (decrease) increase in net assets resulting from operations	\$ (788,992)	\$ 430,159	\$(3,068,066)
Adjustments to reconcile (decrease) increase in net assets from operations to net cash (used in) provided by operating activities:			
Net realized and unrealized (gain) loss on investments	(772,420)	(2,353,182)	1,214,130
Deferred income taxes . .	1,636,817	241,479	(408,655)
Depreciation and amortization	57,426	161,876	271,430
Other	(10,144)	40,859	2,451
Changes in assets and liabilities:			
Receivable from brokers . .	205,789	3,835,602	(4,041,391)
Prepaid expenses	5,475	(21,756)	183,643

Interest receivable	102,376	(227,392)	(64,949)
Taxes receivable	(1,679,377)	1,184,567	(1,190,637)
Other assets	(103,981)	(9,372)	153,071
Accounts payable and accrued liabilities	22,197	(43,241)	142,570
Payable for securities purchased	0	0	(797,380)
Deferred rent	10,279	10,281	20,560
Collection on note receivable	0	54,664	17,105
Purchase of fixed assets	(35,777)	(16,409)	(30,188)
	-----	-----	
Net cash (used in) provided by operating activities	(1,350,332)	3,288,135	(7,596,306)

Cash provided by (used in) investing activities:

Net (purchase) sale of short-term investments and marketable securities	6,035,532	(3,324,957)	9,953,393
Investment in private placements	(4,981,614)	(4,236,352)	(3,671,851)
	-----	-----	
Net cash provided by (used in) investing activities	1,053,918	(7,561,309)	6,281,542

Cash flows provided by financing activities:

Purchase of treasury stock	0	(646,430)	0
Proceeds from exercise of stock options	87,500	62,500	0
Proceeds from private placement of stock (Note 4)	0	5,000,001	0
Proceeds from sale of stock	0	0	1,409,007
	-----	-----	-----
Net cash provided by financing activities	87,500	4,416,071	1,409,007

Net (decrease) increase in cash
and cash equivalents:

Cash and cash equivalents at beginning of the year	364,354	221,457	127,214
Cash and cash equivalents at end of the year	155,440	364,354	221,457

Net (decrease) increase in cash	\$ (208,914)	\$ 142,897	\$ 94,243
	=====	=====	=====

Supplemental disclosures of cash flow information:

Income taxes paid	\$ 57,234	\$ 8,323	\$ 26,820
-----------------------------	-----------	----------	-----------

</TABLE>

The accompanying notes are an integral part of these financial statements.

<TABLE>

<CAPTION>

STATEMENTS OF CHANGES IN NET ASSETS

<S>	<C>	<C>	<C>
	Year Ended	Year Ended	Year Ended
	December 31, 1996	December 31, 1995	December 31, 1994

Changes in net assets from operations:

Net operating loss	\$(1,291,065)	\$(1,099,409)	\$(2,278,882)
Net realized (loss) gain on investments	(2,465,175)	1,371,349	96,856
Net increase (decrease) in unrealized appreciation on investments as a result of sales	1,641,606	(146,372)	(933,059)
Net increase in unrealized appreciation on investments held	1,325,642	304,591	47,019

Net (decrease) increase in net assets resulting from operations	(788,992)	430,159	(3,068,066)
Changes in net assets from capital stock transactions:			
Purchase of stock . . .	0	(646,430)	0
Restricted stock award (Note 3)	0	110,283	220,564
Sales of stock to employees	0	0	1,409,007
Proceeds from exercise of stock options and warrants	87,500	62,500	0
Proceeds from private placement of common stock (Note 4)	0	5,000,001	0
Tax benefit of restricted stock award and common stock transactions	72,186	294,594	0
Net increase in net assets resulting from capital stock transactions . . .	159,686	4,820,948	1,629,571
Net (decrease) increase in net assets.	(629,306)	5,251,107	(1,438,495)
Net assets:			
Beginning of the year . .	36,561,909	31,310,802	32,749,297
End of the year.	\$ 35,932,603	\$ 36,561,909	\$ 31,310,802

</TABLE>

The accompanying footnotes are an integral part of these financial statements.

<TABLE>

<CAPTION>

SCHEDULE OF INVESTMENTS DECEMBER 31, 1996

<S>	<C>	<C>	<C>
	Method of Valuation (3)	Shares/ Principal	Value
	-----	-----	-----
Investments in Unaffiliated Companies			
(9)(12)(13) -- 17.3% of total investments			
Publicly Traded Portfolio -- 9.7% of total investments (Common Stock unless noted otherwise)			
Oil and Gas Related			
CORDEX Petroleum Inc. (1)			
Argentine oil and gas exploration			
Class A Common Stock	(C)	4,052,080	\$ 263,786
Biotechnology and Healthcare Related			
Alliance Pharmaceutical Corporation (1). . (C)		70,000	945,000
Biofield Corp.(1)(4)	(C)	75,000	1,050,938
Magellan Health Services, Inc. (1)(2)(6) . (C)		54,368	1,206,347
Total Publicly Traded Portfolio (cost: \$1,827,774)			\$ 3,466,071
Private Placement Portfolio (Illiquid) -- 7.6% of total investments			
Exponential Business Development Company (1)(2)(5)			
Venture capital partnership focused on early stage companies			
Limited partnership interest.	(A)	--	\$ 25,000
Micracor, Inc. (1)(2) -- Designs and manufactures advanced solid state photonic systems			
Convertible Note.	(D)	\$ 103,000	69,000
Princeton Video Image, Inc. (1)(2)(7)(8) --			

Real time sports and entertainment advertising			
3.5% of fully diluted equity			
Common Stock (B)	68,400		
Warrants at \$2.25 expiring 8/25/97 . . . (D)	6,700	2,613,425	

Total Private Placement Portfolio (cost: \$771,000)		\$ 2,707,425	

Total Investments in			
Unaffiliated Companies (cost: \$2,598,774)		\$ 6,173,496	

</TABLE>

The accompanying notes are an integral part of this schedule.

<TABLE>

<CAPTION>

SCHEDULE OF INVESTMENTS DECEMBER 31, 1996

<S>	<C>	<C>	<C>
	Method of	Shares/	
	Valuation (3)	Principal	Value
	-----	-----	-----

Private Placement Portfolio in Non-Controlled Affiliates
(9)(13) (Illiquid) -- 32.1% of total investments

Dynecology Incorporated (1)(2)(5)(7)			
Develops various environmental intellectual properties -- Option expiring 12/13/98 to purchase at \$15 per share 135,000 shares of Common Stock equaling 18.1% of fully diluted equity(D)	--	\$ 40,000	
Gel Sciences, Inc. (1)(2)(7) -- Develops engineered response gels for controlled release systems -- 10.3% of fully diluted equity Warrants at \$1.65 expiring 02/01/00 . . . (D)		27,766	
Common Stock(B)	171,172		
Series A Preferred Stock(D)	135,178		
Series A-1 Preferred Stock(D)	57,607		
Series B Convertible Preferred Stock . . .(B)	397,409		
Series C Convertible Preferred Stock . . .(B)	101,515	2,349,312	
Harber Brothers Productions, Inc. (1)(2)(5)(7)			
Finances, produces and markets media products that combine entertainment, music, learning and interactivity -- 21.5% of fully diluted equity Series A Voting Convertible Preferred Stock(A)	967,500	967,500	
Highline Capital Management, LLC. (2)(7)			
Organizes and manages investment partnerships 24.9% of fully diluted equity(A)	--	500,000	
Nanophase Technologies Corporation (1)(2)(7)			
Manufactures and markets inorganic crystals of nanometric dimensions 7.6% of fully diluted equity Series D Convertible Preferred Stock . . .(B)	1,162,204	2,614,959	
NeuroMetrix, Inc. (1)(2)(4)(7) -- Developing a device for diabetics to monitor their blood glucose -- 30% of fully diluted equity Warrants at \$1.60 expiring 6/2/97(A)	125,000		
Series A Convertible Preferred Stock . . .(A)	175,000	210,000	
PHZ Capital Partners Limited Partnership (1)(2)(5)			
Organizes and manages investment partnerships 20.0% of fully diluted equity Limited partnership interest(B)	1,000,000		
One year 8% note due 9/22/97(A)	\$ 500,000	500,000	
PureSpeech, Inc. (1)(2)(4)(7) -- Develops and markets innovative speech recognition technology 7.3% of fully diluted equity Series A Convertible Preferred Stock . . .(A)	190,476	999,999	
Questech Corporation (1)(2)(5)(11)			

Manufactures and markets proprietary decorative tiles and signs -- 18.9% of fully diluted equity

Common Stock (B)	565,792	2,263,168
Warrants at \$4.00 expiring 11/28/01 . . . (A)	166,667	167

Total Private Placement Portfolio
in Non-Controlled Affiliates (cost: \$8,381,515) \$11,445,105

</TABLE>

The accompanying notes are an integral part of this schedule.

<TABLE>

<CAPTION>

SCHEDULE OF INVESTMENTS DECEMBER 31, 1996

<S>	<C> Method of Valuation (3)	<C> Shares/ Principal	<C> Value
-----	-----------------------------------	-----------------------------	--------------

Private Placement Portfolio in Controlled Affiliates
(9)(13) (Illiquid) -- 13.1% of total investments

BioSupplyNet, Inc. (1)(2)(4)(7) -- Expands commercially the print and World Wide Web product directories developed by Cold Spring Harbor Laboratory Press -- 34.5% fully diluted equity Series A Voting Convertible Preferred Stock (A)	575,000	\$ 575,000
Genomica Corporation (1)(2)(4)(7)(10) Develops software that enables the study of complex genetic diseases 23.9% of fully diluted equity Common Stock (A)	199,800	
Series A Voting Convertible Preferred Stock (A)	1,660,200	1,000,304
MultiTarget, Inc. (1)(2)(4)(7) -- Developing intellectual property related to localized treatment of cancer 37.5% of fully diluted equity Series A Convertible Preferred Stock (A)	375,000	60,811
nFX Corporation (1)(2) -- Develops neural-network software -- 37.4% of fully diluted equity Series A Voting Convertible Preferred Stock (D)	1,294,288	996,740
Series B Non-Voting Convertible Preferred Stock (D)	689,920	1,539,980
PowerVoice Technologies, Inc. (1)(2)(4)(7) Exploits innovative distributed computing technology for use in small business telephone systems -- 29.2% of fully diluted equity Series A Convertible Preferred Stock (A)	500,000	500,000

Total Private Placement Portfolio
in Controlled Affiliates (cost: \$4,672,835) 4,672,835

U.S. Government Obligations -- 37.5% of total investments

U.S. Treasury Note dated 3/01/93 due date 02/28/98 -- 5.125% rate. (K)	\$ 5,000,000	\$ 4,967,950
U.S. Treasury Bill dated 07/18/96 due date 01/16/97 -- 5.1% yield (H)	1,513,000	1,499,894
U.S. Treasury Bill dated 08/15/96 due date 02/13/97 -- 5.3% yield (H)	3,935,000	3,833,742
U.S. Treasury Bill dated 08/22/96 due date 02/20/97 -- 5.0% yield (H)	1,100,000	1,082,193
U.S. Treasury Bill dated 10/24/96 due date 04/24/97 -- 5.2% yield (H)	1,015,000	998,493

U.S. Treasury Bill dated 12/12/96 due date 06/12/97 -- 5.1% yield (H)	1,000,000	974,974

Total Investments in U.S. Government Obligations (cost: \$13,327,969)	\$ 13,357,246	

Total Investments -- 100% (cost: \$28,981,093)	\$ 35,648,682	
=====		

</TABLE>

The accompanying notes are an integral part of this schedule.

SCHEDULE OF INVESTMENTS DECEMBER 31, 1996

Notes to Schedule of Investments

(1) Represents a non-income producing security. Equity investments that have not paid dividends within the last twelve months are considered to be non-income producing.

(2) Legal restrictions on sale of investment.

(3) See Footnote to Schedule of Investments for a description of the Method of Valuation A to L.

(4) These investments were made during 1996. Accordingly, the amounts shown on the schedule represent the gross additions in 1996.

(5) No activity occurred in these investments during the year ended December 31, 1996.

(6) Formerly named National Mentor Holding Corp., Magellan Health Services, Inc. was later acquired by Charter Medical Corporation, which subsequently changed its name to Magellan Health Services, Inc.

(7) These investments are development stage companies. A development stage company is defined as a company that is devoting substantially all of its efforts to establishing a new business, and either has not yet commenced its planned principal operations or has commenced such operations but has not realized significant revenue from them.

(8) Formerly named Princeton Electronic Billboard, Inc.

(9) Investments in unaffiliated companies consist of investments where Harris & Harris Group, Inc. (the "Company ") owns less than 5 percent of the investee company. Investments in non-controlled affiliated companies consist of investments where the Company owns more than 5 percent but less than 25 percent of the investee company. Investments in controlled affiliated companies consist of investments where the Company owns more than 25 percent of the investee company.

(10) Genomica Corporation was cofounded by the Company, Cold Spring Harbor Laboratory and Falcon Technology Partners, LP. Mr. G. Morgan Browne serves on the Board of the Company and is Administrative Director of Cold Spring Harbor Laboratory.

(11) Formerly named Intaglio, Ltd.

(12) The aggregate cost for federal income tax purposes of investments in unaffiliated companies is \$2,706,451. The gross unrealized appreciation based on tax cost for these securities is \$3,735,334. The gross unrealized depreciation on the cost for these securities is \$268,290.

(13) The percentage ownership of each investee disclosed in the Schedule of Investments expresses the potential common equity interest in each such investee. The calculated percentage represents the amount of issuer's common stock the Company owns or can acquire as a percentage of the issuer's total outstanding common stock plus common shares reserved for issued and outstanding warrants, convertible securities and stock options.

The accompanying notes are an integral part of this schedule.

35

FOOTNOTE TO SCHEDULE OF INVESTMENTS

ASSET VALUATION POLICY GUIDELINES

The Company's investments can be classified into five broad categories for valuation purposes:

- 1) EQUITY-RELATED SECURITIES
- 2) INVESTMENTS IN INTELLECTUAL PROPERTY OR PATENTS OR RESEARCH AND DEVELOPMENT IN TECHNOLOGY OR PRODUCT DEVELOPMENT
- 3) LONG-TERM FIXED-INCOME SECURITIES
- 4) SHORT-TERM FIXED-INCOME INVESTMENTS
- 5) ALL OTHER INVESTMENTS

The Investment Company Act of 1940 (the "1940 Act") requires periodic valuation of each investment in the Company's portfolio to determine net asset value. Under the 1940 Act, unrestricted securities with readily available market quotations are to be valued at the current market value; all other assets must be valued at "fair value" as determined in good faith by or under the direction of the Board of Directors.

The Company's Board of Directors is responsible for 1) determining overall valuation guidelines and 2) ensuring the valuation of investments within the prescribed guidelines.

The Company's Investment and Valuation Committee, comprised of at least three or more Board members, is responsible for reviewing and approving the valuation of the Company's assets within the guidelines established by the Board of Directors.

Fair value is generally defined as the amount that an investment could be sold for in an orderly disposition over a reasonable time. Generally, to increase objectivity in valuing the assets of the Company, external measures of value, such as public markets or third party transactions, are utilized whenever possible. Valuation is not based on long-term work-out value, nor immediate liquidation value, nor incremental value for potential changes that may take place in the future.

Valuation assumes that, in the ordinary course of its business, the Company will eventually sell its investment.

36

The Company's valuation policy with respect to the five broad investment categories is as follows:

EQUITY-RELATED SECURITIES

Equity-related securities are carried at fair value using one or more of the following basic methods of valuation:

A. Cost: The cost method is based on the original cost to the Company. This method is generally used in the early stages of a company's development until significant positive or negative events occur subsequent to the date of the original investment that dictate a change to another valuation method. Some examples of such events are: 1) a major recapitalization; 2) a major refinancing; 3) a significant third-party transaction; 4) the development of a meaningful public market for the company's common stock; 5) significant positive or negative changes in the company's business.

B. Private Market: The private market method uses actual third-party transactions in the company's securities as a basis for valuation, using actual, executed, historical transactions in the company's securities by responsible third parties. The private market method may also use, where

applicable, unconditional firm offers by responsible third parties as a basis for valuation.

C. Public Market: The public market method is used when there is an established public market for the class of the company's securities held by the Company. The Company discounts market value for securities that are subject to significant legal, contractual or practical restrictions, including large blocks in relation to trading volume. Other securities, for which market quotations are readily available, are carried at market value as of the time of valuation.

Market value for securities traded on securities exchanges or on the NASDAQ National Market System is the last reported sales price on the day of valuation. For other securities traded in the over-the-counter market and listed securities for which no sale was reported on that day, market value is the mean of the closing bid price and asked price on that day.

This method is the preferred method of valuation when there is an established public market for a company's securities, as that market provides the most objective basis for valuation.

D. Analytical Method: The analytical method is generally used to value an investment position when there is no established public or private market in the company's securities or when the factual information available to the Company dictates that an investment should no longer be valued under either the cost or private market method. This valuation method is inherently imprecise and ultimately the result of reconciling the judgments of the Company's Investment and Valuation Committee members, based on the data available to them. The resulting valuation, although stated as a precise number, is necessarily within a range of values that vary depending upon the significance attributed to the various factors being considered. Some of the factors considered may include the financial condition and operating results of the company, the long-term potential of the business of the company, the values of similar securities issued by companies in similar businesses, the proportion of the company's securities owned by the Company and the nature of any rights to require the company to register restricted securities under applicable securities laws.

INVESTMENTS IN INTELLECTUAL PROPERTY OR PATENTS OR RESEARCH AND DEVELOPMENT IN TECHNOLOGY OR PRODUCT DEVELOPMENT

Such investments are carried at fair value using the following basic methods of valuation:

E. Cost: The cost method is based on the original cost to the Company. Such method is generally used in the early stages of commercializing or developing intellectual property or patents or research and development in technology or product development until significant positive or adverse events occur subsequent to the date of the original investment that dictate a change to another valuation method.

F. Private Market: The private market method uses actual third-party investments in intellectual property or patents or research and development in technology or product development as a basis for valuation, using actual executed historical transactions by responsible third parties. The private market method may also use, where applicable, unconditional firm offers by responsible third parties as a basis for valuation.

G. Analytical Method: The analytical method is used to value an investment after analysis of the best available outside information where the factual information available to the Company dictates that an investment should no longer be valued under either the cost or private market method. This valuation method is inherently imprecise and ultimately the result of reconciling the judgments of the Company's Investment and Valuation Committee members. The resulting valuation, although stated as a precise number, is necessarily within a range of values that vary depending upon the significance attributed to the various factors being considered. Some of the factors considered may include the results of research and development, product development progress, commercial prospects, term of patent and projected markets.

LONG-TERM FIXED-INCOME SECURITIES

H. Fixed-Income Securities for which market quotations are readily available are carried at market value as of the time of valuation using the most recent bid quotations when available.

38

Securities for which market quotations are not readily available are carried at fair value using one or more of the following basic methods of valuation:

I. Fixed-Income Securities are valued by independent pricing services that provide market quotations based primarily on quotations from dealers and brokers, market transactions, and other sources.

J. Other Fixed-Income Securities that are not readily marketable are valued at fair value by the Investment and Valuation Committee.

SHORT-TERM FIXED-INCOME INVESTMENTS

K. Short-Term Fixed-Income Investments are valued at market value at the time of valuation. Short-term debt with remaining maturity of 60 days or less is valued at amortized cost.

ALL OTHER INVESTMENTS

L. All Other Investments are reported at fair value as determined in good faith by the Investment and Valuation Committee.

The reported values of securities for which market quotations are not readily available and for other assets reflect the Investment and Valuation Committee's judgment of fair values as of the valuation date using the outlined basic methods of valuation. They do not necessarily represent an amount of money that would be realized if the securities had to be sold in an immediate liquidation. The Company makes many of its portfolio investments with the view of holding them for a number of years, and the reported value of such investments may be considered in terms of disposition over a period of time. Thus valuations as of any particular date are not necessarily indicative of amounts that may ultimately be realized as a result of future sales or other dispositions of investments held.

39

NOTES TO FINANCIAL STATEMENTS

NOTE 1. THE COMPANY

Harris & Harris Group, Inc. (the "Company") is a venture capital investment company operating as a business development company ("BDC") under the Investment Company Act of 1940 ("1940 Act"). A BDC is a specialized type of investment company under the 1940 Act. The Company operates as an internally managed investment company whereby its officers and employees, under the general supervision of its Board of Directors, conduct its operations.

The Company elected to become a BDC on July 26, 1995, after receiving the necessary approvals. From July 31, 1992 until the election of BDC status, the Company operated as a closed-end, non-diversified, investment company under the 1940 Act. Upon commencement of operations as an investment company, the Company revalued all of its assets and liabilities at fair value as defined in the 1940 Act. Prior to such time, the Company was registered and filed under the reporting requirements of the Securities and Exchange Act of 1934 as an operating company and, while an operating company, operated directly and through subsidiaries.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies followed in the preparation of the financial statements:

Cash and Cash Equivalents. Cash and cash equivalents include money market instruments with maturities of less than three months.

Portfolio Investment Valuations. Investments are stated at "fair value" as defined in the 1940 Act and in the applicable regulations of the Securities and Exchange Commission. All assets are valued at fair value as determined in good faith by, or under the direction of, the Board of Directors. See the Asset Valuation Policy Guidelines in the Footnote to Schedule of Investments.

Securities Transactions. Securities transactions are accounted for on the date the securities are purchased or sold (trade date); dividend income is recorded on the ex-dividend date; and interest income is accrued as earned. Realized gains and losses on investment transactions are determined on the first-in, first-out basis for financial reporting and tax basis.

Income Taxes. The Company records income taxes using the liability method in accordance with the provision of Statement of Financial Accounting Standards No. 109. Accordingly, deferred tax liabilities have been established to reflect temporary differences between the recognition of income and expenses for financial reporting and tax purposes, the most significant difference of which relates to the Company's unrealized appreciation on investments.

40

Reclassifications. Certain reclassifications have been made to the December 31, 1994 and December 31, 1995 financial statements to conform to the December 31, 1996 presentation.

Estimates by Management. The preparation of the financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of December 31, 1996 and 1995, and the reported amounts of revenues and expenses for the three years ended December 31, 1996. Actual results could differ from these estimates.

NOTE 3. STOCK OPTION PLAN AND WARRANTS OUTSTANDING

On August 3, 1989, the shareholders of the Company approved the 1988 Long Term Incentive Compensation Plan. On June 30, 1994, the shareholders of the Company approved various amendments to the 1988 Long Term Incentive Compensation Plan: 1) to conform to the provisions of the Business Development Company regulations under the 1940 Act, which allow for the issuance of stock options to qualified participants; 2) to increase the reserved shares under the amended plan; 3) to call the plan the 1988 Stock Option Plan, as Amended and Restated (the "1988 Plan"); and 4) to make various other amendments. On October 20, 1995, the shareholders of the Company approved an amendment to the 1988 Plan authorizing automatic 20,000 share grants of non-qualified stock options to newly elected non-employee directors of the Company.

Under the 1988 Plan, the number of shares of common stock of the Company reserved for issuance is equal to 20 percent of the outstanding shares of common stock of the Company at the time of grant. However, so long as warrants, options, and rights issued to persons other than the Company's directors, officers, and employees at the time of grant remain outstanding, the number of reserved shares under the 1988 Plan may not exceed 15 percent of the outstanding shares of common stock of the Company at the time of grant, subject to certain adjustments.

The 1988 Plan provides for the issuance of incentive stock options and non-qualified stock options to eligible employees as determined by the Compensation Committee of the Board (the "Committee"), which is composed of four non-employee directors. The Committee also has the authority to construe and interpret the 1988 Plan, to establish rules for the administration of the 1988 Plan and, subject to certain limitations, to amend the terms and conditions of any outstanding awards. Options may be exercised for up to 10 years from the date of grant at prices not less than the fair market value of the Company's common stock at the date of grant. The 1988 Plan provides that payment by the optionee upon exercise of an option may be made using cash or Company stock held by the optionee.

41

The Company accounts for the 1988 Plan under APB Opinion No. 25, under which no compensation cost has been recognized. Had compensation cost for the 1988 Plan been determined consistent with the fair value method required by FASB Statement No. 123 ("FASB No. 123"), the Company's net realized (loss) income and net asset value per share would have been reduced to the following pro forma amounts:

	1996	1995
Net Realized (Loss) Income:		
As Reported	\$ (3,756,240)	\$ 271,940
Pro Forma	\$ (4,197,096)	\$ (88,752)

Net Asset Value per share:

As Reported	\$3.44	\$3.54
Pro Forma	\$3.40	\$3.51

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

	1996	1995	
Stock volatility	0.60	0.59	
Risk-free interest rate	6.8%	6.5	%
Option term in years	7	7	
Stock dividend yield	--	--	

Because the FASB No. 123 method of accounting has not been applied to options granted prior to January 1, 1995, the resulting pro forma compensation cost and related impact on net realized (loss) income and net asset value per share may not be representative of that value to be expected in future years.

The Company may grant options for up to 2,088,536 shares under the 1988 Plan. The Company has granted options on 1,317,605 shares through December 31, 1996. Under the 1988 Plan, the option exercise price equals the stock's market price on date of grant. The options granted vest over a five year period and expire after 10 years.

42

A summary of the status of the Company's 1988 Plan at December 31, 1996 and 1995 and changes during the years then ended is presented in the table and narrative below:

<TABLE>

	December 31, 1996		December 31, 1995	
	Shares	Weighted Average	Shares	Weighted Average
	Exercise Price	Exercise Price		
Outstanding at beginning of year	1,050,000	\$4.445	678,102	\$1.998
Granted	160,000	\$5.008	742,000	\$5.375
Exercised	50,000	\$1.750	370,102	\$1.778
Forfeited	80,000	\$5.375	-	-
Expired	-	-	-	-
Outstanding at end of year	1,080,000	\$4.584	1,050,000	\$4.445
Exercisable at end of year	390,000	\$3.334	375,212	\$2.788
Weighted average fair value of				

options granted \$3.222 - \$3.424 -

</TABLE>

The range of exercise prices for the outstanding options as of December 31, 1996 are: 8,000 options at \$1.1875, with a remaining life of 4.7 years; 150,000 options at \$1.625, with a remaining life of 2.3 years; 180,000 options at \$3.00 to \$3.75, with an average exercise price of \$3.375 and an average remaining life of 5.1 years; 742,000 options at \$5.375 to \$7.00, with an average exercise price of \$5.485 and an average remaining life of 8.4 years.

As of December 31, 1996, there were outstanding warrants to purchase 237,605 shares of common stock at a price of \$2.0641 per share expiring in 1999.

NOTE 4. CAPITAL STOCK TRANSACTIONS

On May 18, 1995, the Company completed a \$5,000,001 private placement to subsidiaries of American Bankers Insurance Group of 1,075,269 unregistered shares of its common stock at \$4.65 per share, which was the average closing price of Harris & Harris Group on the NASDAQ National Market System during the prior ten trading days. As part of the transaction, American Bankers has been granted certain registration rights and has executed a standstill agreement.

43

NOTE 5. EMPLOYEE BENEFITS

As of August 15, 1990, the Company entered into a non-competition, employment and severance contract with its Chairman, Charles E. Harris, pursuant to which he is to receive compensation in the form of salary and other benefits. This contract was amended on June 30, 1992, January 3, 1993, and June 30, 1994. The term of the contract expires on December 31, 1999.

Base salary is to be increased annually to reflect inflation and in addition may be increased by such amount as the Compensation Committee of the Board of Directors of the Company deems appropriate.

In addition, Mr. Harris would be entitled, under certain circumstances, to receive severance pay under the employment and severance contracts.

As of January 1, 1989, the Company adopted an employee benefits program covering substantially all employees of the Company under a 401(k) Plan and Trust Agreement. During 1996, contributions to the plan that have been charged to operations totaled \$40,254.

On June 30, 1994, the Company adopted a plan to provide medical and health coverage for retirees, their spouses and dependents who, at the time of their retirement, have ten years of service with the Company and have attained 50 years of age or have attained 45 years of age and have 15 years of service with the Company. On February 10, 1997, the Company amended this plan to include employees who "have seven full years of service and have attained 58 years of age." The coverage is secondary to any government provided or subsequent employer provided health insurance plans. Based upon actuarial estimates, the Company provided an original reserve of \$176,520 that was charged to operations for the period ending June 30, 1994. As of December 31, 1996, the Company had a reserve of \$206,630 for the plan.

NOTE 6. INCOME TAXES

The Company has not elected tax treatment available to regulated investment companies under Sub-Chapter M of the Internal Revenue Code. Accordingly, for federal and state income tax purposes, the Company is taxed at statutory corporate rates on its income, which enables the Company to offset any future net operating losses against prior years' net income. The Company may carry back operating losses against net income three years and carry forward such losses fifteen years.

44

For the years ended December 31, 1996, 1995 and 1994, the Company's income tax (benefit) provision was allocated as follows:

<TABLE>

<S> <C> <C> <C>

	1996	1995	1994
Investment Operations	\$ (680,834)	\$(597,215)	\$(1,265,648)
Realized (loss) gain on investments	(1,327,401)	738,419	(168,252)
Increase (decrease) in unrealized appreciation on investments	1,597,748	85,195	(256,694)
	-----	-----	-----
Total income tax (benefit) provision	\$ (410,487)	\$ 226,399	\$(1,690,594)
	=====	=====	=====

The above tax (benefit) provision consists of the following:

Current -- Federal	\$(2,047,304)	\$ (38,319)	\$(1,281,939)
Deferred -- Federal	1,636,817	264,718	(408,655)
	-----	-----	-----
Total income tax (benefit) provision	\$ (410,487)	\$ 226,399	\$(1,690,594)
	=====	=====	=====

</TABLE>

The Company's deferred tax liability at December 31, 1996 and 1995 consists of the following:

<TABLE>

	<C>	<C>
	1996	1995
Unrealized appreciation on investments	\$ 2,295,998	\$ 698,250
Medical retirement benefits	(72,320)	(72,320)
Other	(36,231)	(75,300)
	-----	-----
Net deferred income tax liability	\$ 2,187,447	\$ 550,630
	=====	=====

</TABLE>

NOTE 7. COMMITMENTS AND CONTINGENCIES

During 1993, the Company signed a ten-year lease with sublet provisions for office space. In 1995, this lease was amended to include additional office space. Rent expense under this lease for the year ended December 31, 1996, was \$160,601. Future minimum lease payments in each of the following years are: 1997 -- \$164,484; 1998 -- \$168,768; 1999 -- \$176,030; 2000 -- \$178,561; 2001 -- \$178,561; thereafter \$280,507.

The Company has guaranteed a three-year lease obligation of approximately \$21,000 per annum for the office space of one of its investees, Highline Capital Management LLC.

In December 1993, the Company and MIT announced the establishment by the Company of the Harris & Harris Group Senior Professorship at MIT. Prior to the arrangement for the establishment of this Professorship, the Company had made gifts of stock in start-up companies to MIT. These gifts, together with the contribution of \$700,000 in cash in 1993, which was expensed by the Company in 1993, were used to establish this named chair.

The Company contributed to MIT securities with a cost basis of \$3,280, \$20,000 and \$20,000 in 1993, 1994, and 1995 respectively. These contributions will be applied to the MIT Pledge at their market value at the time the shares become publicly traded or otherwise monetized in a commercial transaction and are free from restriction as to sale by MIT.

45

At December 31, 1996, the Company would have to fund additional cash and/or property that would have to be valued at a total of \$756,720 by December, 1998, in order for the Senior Professorship to become permanent.

NOTE 8. SUBSEQUENT EVENTS

In January 1997, the Company signed loan agreements with two of its investee companies for up to \$750,000. In addition, the Company has guaranteed a bonus of up to \$100,000 to the key employees of one of its investee companies.

Also in January 1997, the Company made a follow-on investment of \$850,000 in PowerVoice Technologies. In addition, the Company invested \$500,000 in Highline Offshore Investors.

<TABLE>
<CAPTION>

SELECTED PER SHARE DATA AND RATIOS

Per share operating performance:

<S>	<C>	<C>	<C>	<C>	<C>
	Year Ended	Year Ended	Year Ended	Year Ended	3 Months Ended
	December 31,	December 31,	December 31,	December 31,	December 31,
	1996	1995	1994	1993	1992

Net asset value, beginning of period \$	3.54 \$	3.43 \$	3.66 \$	2.71 \$	2.90
---	---------	---------	---------	---------	------

Net operating loss	(0.12)	(0.11)	(0.25)	(0.19)	(0.02)
-----------------------	--------	--------	--------	--------	--------

Net realized (loss) gain	(0.24)	0.14	0.01	2.75	(0.02)
-----------------------------	--------	------	------	------	--------

Net increase (decrease) in unrealized appreciation as a result of sales	0.16	(0.01)	(0.11)	(1.78)	(0.01)
--	------	--------	--------	--------	--------

Net increase (decrease)in unrealized appreciation on investments held	0.13	0.03	0.01	0.25	(0.14)
--	------	------	------	------	--------

Net (decrease) increase from capital stock transactions	(0.03)	0.06	0.11	(0.08)	0
--	--------	------	------	--------	---

Net asset value, end of period \$	3.44 \$	3.54 \$	3.43 \$	3.66 \$	2.71
---	---------	---------	---------	---------	------

Market value per share, end of period \$	3.75 \$	7.875 \$	6.375 \$	8.250 \$	4.375
---	---------	----------	----------	----------	-------

Deferred income tax per share \$	0.21 \$	0.050 \$	0.030 \$	0.080 \$	0.760
--	---------	----------	----------	----------	-------

Ratio of expenses to average net assets	8.1%	8.3%	13.6%	11.3%	2.0%
---	------	------	-------	-------	------

Ratio of net operating loss to average net assets	3.5%	3.2%	7.1%	6.0%	6.7%
--	------	------	------	------	------

Investment return based on:					
Stock price	(52.4)%	23.5%	(22.7)%	88.6%	49.0%
Net asset value	(2.8)%	3.2%	(6.3)%	35.0%	(6.5)%

Portfolio turnover	51.2%	51.2%	136.4%	118.1%	8.7%
--------------------	-------	-------	--------	--------	------

Net assets, end of period \$	35,932,603	\$ 36,561,909	\$ 31,310,802	\$ 32,749,297	\$ 22,653,343
---------------------------------	------------	---------------	---------------	---------------	---------------

Number of
shares
outstanding 10,442,682 10,333,902 9,136,747 8,944,828 8,350,999

</TABLE>

The accompanying notes are an integral part of this schedule.

CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

As independent public accountants, we hereby consent to the incorporation by reference in this Form 10-K of our report dated February 6, 1997. It should be noted that we have not audited any financial statements of the company subsequent to December 31, 1996 or performed any audit procedures subsequent to the date of our report.

Arthur Andersen LLP

New York, New York
March 27, 1997

<TABLE> <S> <C>

<ARTICLE> 6

<CIK> 0000893739

<NAME> HARRIS & HARRIS GROUP, INC.

<S>	<C>
<PERIOD-TYPE>	12-MOS
<FISCAL-YEAR-END>	DEC-31-1996
<PERIOD-END>	DEC-31-1996
<INVESTMENTS-AT-COST>	28,981,093
<INVESTMENTS-AT-VALUE>	35,648,682
<RECEIVABLES>	2,317,834
<ASSETS-OTHER>	351,833
<OTHER-ITEMS-ASSETS>	81,501
<TOTAL-ASSETS>	38,555,290
<PAYABLE-FOR-SECURITIES>	0
<SENIOR-LONG-TERM-DEBT>	0
<OTHER-ITEMS-LIABILITIES>	2,622,687
<TOTAL-LIABILITIES>	2,622,687
<SENIOR-EQUITY>	0
<PAID-IN-CAPITAL-COMMON>	15,850,576
<SHARES-COMMON-STOCK>	10,442,682
<SHARES-COMMON-PRIOR>	10,333,902
<ACCUMULATED-NII-CURRENT>	0
<OVERDISTRIBUTION-NII>	0
<ACCUMULATED-NET-GAINS>	15,606,009
<OVERDISTRIBUTION-GAINS>	0
<ACCUM-APPREC-OR-DEPREC>	4,371,591
<NET-ASSETS>	35,932,603
<DIVIDEND-INCOME>	8,024
<INTEREST-INCOME>	803,819
<OTHER-INCOME>	201,574
<EXPENSES-NET>	2,985,316
<NET-INVESTMENT-INCOME>	(1,291,065)
<REALIZED-GAINS-CURRENT>	(2,465,175)
<APPREC-INCREASE-CURRENT>	2,967,248
<NET-CHANGE-FROM-OPS>	(788,992)
<EQUALIZATION>	0
<DISTRIBUTIONS-OF-INCOME>	0
<DISTRIBUTIONS-OF-GAINS>	0
<DISTRIBUTIONS-OTHER>	0
<NUMBER-OF-SHARES-SOLD>	0
<NUMBER-OF-SHARES-REDEEMED>	0
<SHARES-REINVESTED>	0
<NET-CHANGE-IN-ASSETS>	(788,992)
<ACCUMULATED-NII-PRIOR>	0
<ACCUMULATED-GAINS-PRIOR>	0
<OVERDISTRIB-NII-PRIOR>	0
<OVERDIST-NET-GAINS-PRIOR>	0
<GROSS-ADVISORY-FEES>	0
<INTEREST-EXPENSE>	0
<GROSS-EXPENSE>	0
<AVERAGE-NET-ASSETS>	36,247,256
<PER-SHARE-NAV-BEGIN>	3.54
<PER-SHARE-NII>	0
<PER-SHARE-GAIN-APPREC>	0
<PER-SHARE-DIVIDEND>	0
<PER-SHARE-DISTRIBUTIONS>	0
<RETURNS-OF-CAPITAL>	0
<PER-SHARE-NAV-END>	3.44
<EXPENSE-RATIO>	0
<AVG-DEBT-OUTSTANDING>	0
<AVG-DEBT-PER-SHARE>	0

</TABLE>